Contribution of systemic inflammation to permanence of KATP -induced neonatal diabetes in mice

American Journal of Physiology. Endocrinology and Metabolism
Christopher H EmfingerMaria Sara Remedi

Abstract

Gain-of-function (GOF) mutations in the ATP-sensitive potassium (KATP) channels cause neonatal diabetes. Despite the well-established genetic root of the disease, pathways modulating disease severity and treatment effectiveness remain poorly understood. Patient phenotypes can vary from severe diabetes to remission, even in individuals with the same mutation and within the same family, suggesting that subtle modifiers can influence disease outcome. We have tested the underlying mechanism of transient vs. permanent neonatal diabetes in KATP-GOF mice treated for 14 days with glibenclamide. Some KATP-GOF mice show remission of diabetes and enhanced insulin sensitivity long after diabetes treatment has ended, while others maintain severe insulin-resistance. However, insulin sensitivity is not different between the two groups before or during diabetes induction, suggesting that improved sensitivity is a consequence, rather than the cause of, remission, implicating other factors modulating glucose early in diabetes progression. Leptin, glucagon, insulin, and glucagon-like peptide-1 are not different between remitters and nonremitters. However, liver glucose production is significantly reduced before transgene induction in remitter, re...Continue Reading

References

Dec 12, 2002·Diabetes·Patrick E MacDonaldMichael B Wheeler
May 18, 2004·Endocrine·Stephen E Borst
Nov 27, 2004·Human Genetics·Michael J RiedelPeter E Light
Feb 19, 2005·Human Molecular Genetics·Anna L GloynAndrew T Hattersley
Jul 11, 2006·The Journal of Clinical Investigation·Steven E ShoelsonAllison B Goldfine
Aug 4, 2006·The New England Journal of Medicine·Ewan R PearsonUNKNOWN Neonatal Diabetes International Collaborative Group
Dec 15, 2006·Nature·Gökhan S Hotamisligil
Mar 29, 2007·Diabetes·Martine VaxillaireUNKNOWN SUR1-Neonatal Diabetes Study Group
Apr 13, 2007·Physiological Reviews·David B SavageGerald I Shulman
Sep 8, 2007·The Review of Diabetic Studies : RDS·Christos PitsavosChristodoulos Stefanadis
Oct 18, 2007·Journal of Animal Science·M LorenzoI Nieto-Vazquez
Jan 4, 2008·Acta Physiologica·S Glund, A Krook
Mar 3, 2009·Vitamins and Hormones·Jeong-Ho KimJie Chen
Aug 1, 2009·Science·Chang-Liang ZhangSusumu Seino
Nov 19, 2009·Pflügers Archiv : European journal of physiology·Maria S Remedi, Joseph C Koster
Jun 16, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·K ShimomuraF M Ashcroft
Apr 30, 2011·Physiological Reviews·Gregory J Morton, Michael W Schwartz
May 28, 2011·Diabetes, Obesity & Metabolism·J I BaggerT Vilsbøll
Apr 16, 2013·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Regina Arantes-RodriguesPaula Oliveira
Jul 19, 2013·The Journal of Clinical Investigation·Shuangli GuoRoland Stein
Jan 15, 2014·Cell Metabolism·Helene L Kammoun, Mark A Febbraio
Feb 13, 2014·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Joel MontaneAnna Novials
May 24, 2014·Nature Reviews. Drug Discovery·Marc Y Donath
Aug 26, 2014·Nature Communications·Melissa F BreretonFrances M Ashcroft
Feb 13, 2015·Proceedings of the National Academy of Sciences of the United States of America·May-Yun WangRoger H Unger
Feb 26, 2015·Diabetes Care·Bess A MarshallColin G Nichols
Dec 30, 2015·The Journal of Clinical Endocrinology and Metabolism·Francesca CintiDomenico Accili
Feb 13, 2016·Journal of Hepatology·Dirk Schmidt-Arras, Stefan Rose-John

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
ELISA
Assay
transgenics

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here